Shenzhen Chipscreen Biosciences Co Ltd
SSE:688321

Watchlist Manager
Shenzhen Chipscreen Biosciences Co Ltd Logo
Shenzhen Chipscreen Biosciences Co Ltd
SSE:688321
Watchlist
Price: 19.56 CNY 0.93% Market Closed
Market Cap: 8B CNY
Have any thoughts about
Shenzhen Chipscreen Biosciences Co Ltd?
Write Note

Operating Margin
Shenzhen Chipscreen Biosciences Co Ltd

-3.4%
Current
-8%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-3.4%
=
Operating Profit
-22.3m
/
Revenue
656.2m

Operating Margin Across Competitors

Country CN
Market Cap 8B CNY
Operating Margin
-3%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 749.1B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 2.7T DKK
Operating Margin
44%
Country US
Market Cap 348B USD
Operating Margin
28%
Country US
Market Cap 251.1B USD
Operating Margin
34%
Country CH
Market Cap 200.1B CHF
Operating Margin
32%
Country UK
Market Cap 161.8B GBP
Operating Margin
21%
Country CH
Market Cap 171.5B CHF
Operating Margin
31%
Country US
Market Cap 150.1B USD
Operating Margin
22%
No Stocks Found

Shenzhen Chipscreen Biosciences Co Ltd
Glance View

Market Cap
8B CNY
Industry
Pharmaceuticals

In the bustling city of Shenzhen, often hailed as China's Silicon Valley, Shenzhen Chipscreen Biosciences Co Ltd stands as a testament to innovation in the biopharmaceutical landscape. Founded in 2001, the company embarked on a journey to bridge the gap between cutting-edge bioscience and market needs, focusing on research, development, and commercialization of novel drugs. Chipscreen’s core strength lies in its proprietary chemical genomics-based discovery and development platform, which has carved out a niche in identifying molecular targets and mining drug candidates with high therapeutic potential. The company seamlessly integrates advanced technologies with biotech prowess to design and develop small molecule drugs that address unmet clinical needs, primarily focusing on oncology, autoimmune diseases, and metabolic disorders. The financial engine of Chipscreen Biosciences hums through a well-orchestrated portfolio strategy. By progressing drug candidates through various stages of clinical trials, the company has not only diversified its offerings but also strategically positioned itself in lucrative therapeutic markets. Its revenue model capitalizes on successful product commercialization, primarily through sales of its marketed drugs and royalties from licensing agreements with strategic partners. This collaborative approach enables Chipscreen to maximize its product reach while sharing developmental risks. As the company's innovative therapies gain traction in domestic and global markets, Chipscreen continues its commitment to reinvest in research and development, crafting a sustainable cycle of growth fueled by scientific advancement and strategic acumen.

Intrinsic Value
12.34 CNY
Overvaluation 37%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-3.4%
=
Operating Profit
-22.3m
/
Revenue
656.2m
What is the Operating Margin of Shenzhen Chipscreen Biosciences Co Ltd?

Based on Shenzhen Chipscreen Biosciences Co Ltd's most recent financial statements, the company has Operating Margin of -3.4%.